Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 11/20 | 0.33 |
| ▸ | SRC | P12931 | 11/20 | 0.33 |
| ▸ | PDE9A | O76083 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876223 | 0.81 | PDE2A (0.40) | PDE2A | |
| SCHEMBL25875949 | 0.81 | ADORA3 (0.42) | PDE2A | |
| SCHEMBL25876313 | 0.79 | CYP17A1 (0.43) | PDE2A | |
| SCHEMBL25876283 | 0.78 | PDE1A (0.44) | PDE2A | |
| SCHEMBL30327625 | 0.78 | PDE10A (0.34) | — | |
| SCHEMBL25876067 | 0.75 | PDE1A (0.41) | PDE2A | |
| SCHEMBL30328297 | 0.73 | HTR2A (0.33) | — | |
| SCHEMBL29202302 | 0.73 | HTR2A (0.33) | — | |
| SCHEMBL30328461 | 0.72 | PDE9A (0.37) | PDE9A | |
| SCHEMBL31051055 | 0.72 | PDE9A (0.44) | PDE2APDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PDE2A 1000/4885ABL1 18/4885SRC 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.